December 15, 2006
ROCKVILLE, Md. -- Two FDA advisory committees agreed today that the antibiotic Ketek (telithromycin) should be limited to second-line therapy for community-acquired pneumonia, and that the drug should have black box warning added to its label.
December 15, 2006
ROCKVILLE, Md. -- The FDA announced today it had narrowed the indications for Trasylol (aprotinin injection), a drug used control bleeding during heart surgery, partly because of belatedly revealed risks of death or serious kidney damage.
December 15, 2006
ROCKVILLE, Md. -- The FDA announced today it had narrowed the indications for Trasylol (aprotinin injection), a drug used control bleeding during heart surgery, partly because of belatedly revealed risks of death or serious kidney damage.
December 14, 2006
BETHESDA, Md. -- Two U.S.-led trials of men in sub-Saharan Africa were halted early when interim analyses of results confirmed that circumcision can significantly reduce heterosexual transmission of HIV.
December 14, 2006
BETHESDA, Md. -- Two U.S.-led trials of men in sub-Saharan Africa were halted early when interim analyses of results confirmed that circumcision can significantly reduce heterosexual transmission of HIV.
December 13, 2006
ROCKVILLE, Md. -- Frozen oysters on the half shell, imported from South Korea and distributed to five states, have been linked by the FDA and CDC to a small outbreak of norovirus in Oregon.
December 13, 2006
ROCKVILLE, Md. -- Frozen oysters on the half shell, imported from South Korea and distributed to five states, have been linked by the FDA and CDC to a small outbreak of norovirus in Oregon.
December 13, 2006
ROCKVILLE, Md. -- Frozen oysters on the half shell, imported from South Korea and distributed to five states, have been linked by the FDA and CDC to a small outbreak of norovirus in Oregon.
December 08, 2006
GAITHERSBURG, Md. -- Midway through a two-day FDA hearing on the safety of drug-eluting coronary stents the hard questions were still open.
December 06, 2006
GAITHERSBURG, Md. -- There are more questions than answers on the eve of the start of a two-day special FDA advisory panel on drug-eluting stents, such as whether they are safe, who should get get them, and who should not.